PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
21.98%
Revenue growth above 1.5x AVGO's 7.51%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
25.31%
Gross profit growth above 1.5x AVGO's 7.73%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
30.69%
EBIT growth 1.25-1.5x AVGO's 22.15%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
30.69%
Operating income growth 1.25-1.5x AVGO's 22.15%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
32.91%
Net income growth under 50% of AVGO's 330.61%. Michael Burry would suspect the firm is falling well behind a key competitor.
31.58%
EPS growth under 50% of AVGO's 330.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
32.43%
Diluted EPS growth under 50% of AVGO's 325.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.08%
Share reduction while AVGO is at 0.34%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.16%
Reduced diluted shares while AVGO is at 3.54%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
2.14%
Dividend growth above 1.5x AVGO's 0.96%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
56.83%
OCF growth above 1.5x AVGO's 12.92%. David Dodd would confirm a clear edge in underlying cash generation.
59.41%
FCF growth above 1.5x AVGO's 14.42%. David Dodd would verify if the firm’s strategic investments yield superior returns.
1681.26%
10Y revenue/share CAGR above 1.5x AVGO's 379.83%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
890.21%
5Y revenue/share CAGR above 1.5x AVGO's 106.45%. David Dodd would look for consistent product or market expansions fueling outperformance.
343.59%
3Y revenue/share CAGR above 1.5x AVGO's 67.49%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
2546.14%
10Y OCF/share CAGR above 1.5x AVGO's 698.46%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1164.93%
5Y OCF/share CAGR above 1.5x AVGO's 91.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
458.57%
3Y OCF/share CAGR above 1.5x AVGO's 39.70%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
7610.59%
Net income/share CAGR above 1.5x AVGO's 1638.73% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2040.31%
5Y net income/share CAGR above 1.5x AVGO's 333.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
746.59%
3Y net income/share CAGR above 1.5x AVGO's 91.90%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
789.30%
10Y equity/share CAGR at 75-90% of AVGO's 1032.87%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
354.45%
5Y equity/share CAGR above 1.5x AVGO's 129.97%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
155.44%
3Y equity/share CAGR 1.25-1.5x AVGO's 139.07%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
88.89%
Below 50% of AVGO's 1564.74%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
-0.21%
Negative 5Y dividend/share CAGR while AVGO stands at 99.96%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
0.41%
Below 50% of AVGO's 40.47%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
20.34%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
10.53%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
21.39%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
29.30%
BV/share growth above 1.5x AVGO's 2.74%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.26%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
7.45%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
3.34%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.